venBio Rings In 2013 With Two Company Launches
This article was originally published in The Pink Sheet Daily
New venture firm venBio, which closed its inaugural $200 million fund in 2010, has begun the new year by unveiling two start ups with very different business propositions.
You may also be interested in...
Labrys is ready to advance a monoclonal antibody to Phase II for prevention of chronic migraine, after releasing pooled safety from five Phase I trials conducted by Pfizer.
Biopharma financing reached $4.6 billion in Q1 2013, exceeding Q4 2012’s $4.2 billion total, mostly through follow-on public offerings, which made up 47% of the total funding. Conversely, M&A was on the decline with 18 completed transactions together valued at $4.8 billion, the lowest quarter since 2009. The $5.5 billion potential deal value aggregate for alliances more than doubled from the previous quarter, mainly due to Biogen Idec’s $3.25 billion buy of Elan's share of multiple sclerosis drug Tysabri.
Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.